FDA
-
-
-
-
-
-
-
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
Altimmune (ALT) Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
-
-
-
-
-
-
-
Pre-Open Stock Movers 12/24: (BABA) (SENS) (TNXP) (GEVO) (ALT) (more...)
-
-
-
-
-
-
-
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
-
-
-
-
-
-
-
Altimmune Announces Successful Completion of Multiple Dose Toxicity and Toxicokinetic Studies of ALT-801, a GLP-1/Glucagon Dual Receptor Agonist for the Treatment of NASH
-
-
-
-
-
-
-
Pre-Open Stock Movers 07/15: (FVAC) (MRNA) (CCL) Higher; (VXRT) (ZYXI) (BK) Lower (more...)
-
-
-
-
-
-
-
Pre-Open Stock Movers 06/29: (KNSA) (WKHS) (COTY) Higher; (ICPT) (HRTX) (BYND) Lower (more...)
-
251,872 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All